Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.63
Schlusskurs vom Vortag:
$4.63
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$533.68M
Einnahmen:
$3.91M
Nettoeinkommen (Verlust:
$-206.53M
KGV:
0.00
EPS:
-2.4825
Netto-Cashflow:
$-167.78M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$6.79
I Mab Adr Stock (IMAB) Company Profile
Vergleichen Sie IMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
0.00 | 533.68M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-03 | Eingeleitet | Leerink Partners | Outperform |
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2021-12-09 | Eingeleitet | Siebert Williams Shank | Buy |
| 2021-06-02 | Eingeleitet | Daiwa Securities | Buy |
| 2021-03-15 | Eingeleitet | Needham | Buy |
| 2021-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-25 | Eingeleitet | Piper Sandler | Overweight |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-12 | Eingeleitet | China Renaissance | Buy |
| 2020-02-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
I Mab Adr Aktie (IMAB) Neueste Nachrichten
Mitchells & Butlers (LON:MAB) Shares Up 7.2% – Should You Buy? - Defense World
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer - Sahm
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN
I-Mab (IMAB) Expected to Announce Earnings on Thursday - Defense World
Short Interest in I-Mab Sponsored ADR (NASDAQ:IMAB) Increases By 38.8% - MarketBeat
What date does NOVABRIDGE BIOS's (NBP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
NovaBridge Biosciences (NAS:NBP) Stock News, Headlines & Updates - GuruFocus
NovaBridge Biosciences (NBP) Stock Price, Trades & News - GuruFocus
NOVABRIDGE BIOS (NBP) - Zacks Investment Research
Total assets of I-Mab Sponsored ADR – NASDAQ:NBP - TradingView
I-Mab Sponsored ADR Statistics – NASDAQ:NBP - TradingView
NBP Stock Price and Chart — NASDAQ:NBP - TradingView
NBPNovaBridge Biosciences. ADR Stock Price and Quote - Finviz
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-MabIMAB - WV News
I-Mab’s (IMAB) Buy Rating Reiterated at BTIG Research - Defense World
I-Mab Sponsored ADR (NASDAQ:IMAB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
I-Mab stock reaffirmed as Buy at H.C. Wainwright on positive cancer drug data - Investing.com India
I-Mab stock reaffirmed as Buy at H.C. Wainwright on positive cancer drug data By Investing.com - Investing.com South Africa
I-Mab Rebrands to NovaBridge Biosciences Following Shareholder Approval - TipRanks
I-Mab reports 18% response rate for givastomig in gastric cancer trial - Investing.com India
I-Mab reports 18% response rate for givastomig in gastric cancer trial By Investing.com - Investing.com South Africa
Is Wolfspeed Inc (WOLF) positioned for future growth? - setenews.com
Using data filters to optimize entry into I Mab Depositary Receipt2025 Market Overview & Growth Focused Investment Plans - newser.com
I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift - Investing.com India
I-Mab stock price target raised to $10 by Jefferies on rebranding, new asset - Investing.com India
I-Mab to rebrand as NovaBridge Biosciences, plans Hong Kong IPO - Investing.com Philippines
I-Mab (IMAB) Unveils Strategic Shift with New Business Model and Dual Listing Plan - GuruFocus
I-Mab to rebrand as NovaBridge Biosciences, plans Hong Kong IPO By Investing.com - Investing.com South Africa
I-Mab (NASDAQ:IMAB) Hits New 1-Year HighTime to Buy? - MarketBeat
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference - GlobeNewswire Inc.
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know - MSN
Its Stock Has Paid Off Big Time For Liveperson Inc - setenews.com
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday - Benzinga
What Makes IMab (IMAB) a New Buy Stock - sharewise.com
I-Mab Sponsored ADR (NASDAQ:IMAB) Given Average Rating of "Buy" by Analysts - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Adversity is less terrifying than hope: Navitas Semiconductor Corp (NVTS) - setenews.com
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket - Benzinga
I-Mab at H.C. Wainwright Conference: Strategic U.S. Shift and Jeva Stomach Focus - Investing.com
I-Mab (NASDAQ:IMAB) Now Covered by BTIG Research - Defense World
I-Mab stock initiated with Buy rating at BTIG on gastric cancer drug potential - Investing.com
I-Mab (NASDAQ:IMAB) Receives Buy Rating from Needham & Company LLC - Defense World
I-Mab to initiate phase 2 study for gastric cancer drug in Q1 2026 - Investing.com
Adverse Reactions to Tremelimumab, Durvalumab in Liver Cancer - Bioengineer.org
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce… - inkl
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAcadian Asset Management (NYSE:AAMI), C3.ai (NYSE:AI) - Benzinga
Equities Analysts Offer Predictions for I-Mab Q3 Earnings - MarketBeat
I-Mab stock price target raised to $8 from $6 at Brookline Capital - Investing.com
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice - Yahoo Finance
Finanzdaten der I Mab Adr-Aktie (IMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):